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T he Ongoing Telmisartan Alone and in Combination
with Ramipril Global Endpoint Trial (ONTARGET) 1 has shown that in patients at high cardiovascular (CV) risk a treatment regimen based on telmisartan or ramipril reduced to a similar degree clinic blood pressure (BP) and showed no significant difference in the incidence of CV morbid or fatal events. Clinic BP was reduced to a somewhat greater degree in patients treated with a combination of the 2 drugs (1.5-2.4 mm Hg systolic BP [SBP] and 0.8-1.4 mm Hg diastolic BP [DBP]), without, however, any significant difference in CV outcome. Because ramipril had been shown previously to reduce outcomes in high CV risk individuals 2 ; this led to the conclusion that telmisartan and ramipril have a similar protective effect, which is not enhanced by double blockade of the renin-angiotensin system, despite the potentially greater protection associated with a greater BP-lowering effect. 3 Evidence is available that BP reductions induced by antihypertensive treatment cannot be precisely quantified if BP is measured in the clinic environment because clinic BP is affected to a variable degree by a transient increase known as the white coat effect. 4 Furthermore, clinic BP values are poorly reproducible, 5, 6 and their treatment-induced changes reflect to only a modest degree the concomitant changes in daily life BP, 7-10 that is, a more reproducible 5 and prognostically important BP, which relates more steeply to CV morbidity and mortality. [11] [12] [13] [14] [15] [16] [17] The ONTARGET included a prespecified substudy 18 focusing on ambulatory BP (ABP) to determine whether and to what extent treatment-induced changes in clinic BP correspond to daily life ABP. This article reports the results. disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus complicated by organ damage, were randomly assigned to ramipril (5 mg and then 10 mg QD), telmisartan (80 mg QD), or their combination. The drugs were administered on top of preexisting treatment after a run-in period of 11 to 18 days during which reduced doses of either drug were given to exclude patients intolerant to the study medications. One month after randomization and every 6 months thereafter, 25 620 patients from 733 centers in 40 countries were randomized and evaluated at baseline. The median follow-up period was 4.7 years. The primary end point was a composite of CV death, myocardial infarction, stroke, or hospitalization for heart failure (first occurrence).
The ABP monitoring substudy involved 33 centers from 9 countries (Argentina, Australia, Belgium, Brazil, France, Hungary, Italy, South Africa, and Spain). Centers participated on a voluntary basis, and patients undergoing ABP monitoring were not randomized. Patients underwent a 24-hour (h) ABP monitoring before the run-in period (baseline) and then between 6 and 24 months after randomization, that is, when drug titration had long been completed and therapy was stable. Because this ABP study was initiated after the main study had started, we also included individuals with only on-treatment 24-hour ABP monitoring, which allowed comparison of ABP values under the 3 drug regimens in a larger number of patients. ABP monitoring was performed with a variety of oscillometric devices (Spacelabs, TM 2430 and Meditech), all validated according to international protocols 19, 20 and programmed to measure BP every 15 minutes during the day (6:00 am to 12:00 am) and every 20 minutes during the night (12:00 am to 6:00 am). The monitoring cuff was applied around the nondominant arm, usually in the morning, before intake of the study drug(s). Patients were then sent home and instructed to lead a normal life but to keep the arm extended and immobile during the cuff inflation. They were also instructed to record the times of the main daily activities (meals, sleep, etc), to note unusual events, and to come back the following day for the device removal.
Data Analysis
ABP monitoring data were sent to a reading center (Istituto Auxologico Italiano, Milan, Italy) where they were checked for quality. Data were regarded as suitable for further analysis if they met several prespecified criteria, as adopted by international guidelines, 21 namely the following: (1) the recording lasted ≥24 hours; (2) ≥70% of the expected number of readings was available; (3) there was ≥1 valid measurement per hour. Single measurements were regarded as valid as follows:
(1) if SBP was not >300 mm Hg or <50 mm Hg; (2) if DBP was not >150 mm Hg or <40 mm Hg; (3) if heart rate was not >150/min or <40/ min; (4) if pulse pressure (difference between SBP and DBP) was >0 and not >150 mm Hg. In the overall population, the average number of valid readings was 82+13, that is, 91% of the expected number of readings (n=90) for 24-hour, daytime, nighttime, and hourly SBP, DBP, and heart rate means were obtained from each ABP recording. Baseline, on-treatment, and changes from baseline values were calculated separately for the 3 treatment groups. We calculated the on-treatment SBP and DBP smoothness indices, 22, 23 which were obtained by the ratio between the mean and the SD of the hourly BP changes induced by treatment. This provided a normalized measure of the homogeneity of BP reduction throughout the 24 hours, which has been shown to have a normal distribution, a high reproducibility, and an independent relationship with left ventricular mass and carotid intima-media thickness. 22, 23 ABP values were compared with clinic BP values (mean of 2 measurements in the sitting position 3 months apart) obtained by a semiautomatic device (OMRON, model HEM-757) 1, 18 at the visit when ABP monitoring was started. Between-group comparisons were made by unpaired (different treatments) or paired (treatment versus pretreatment) t tests. P values for the BP changes induced by treatment were calculated after adjustment for baseline BP. The t tests were 2 sided and the Tukey method was used for multiple comparisons. Data from the different groups were pooled to calculate clinic-ABP differences at baseline and during treatment according to the target clinic SBP values recommended by guidelines or used in trials on high CV risk patients. 24, 25 Pooled data were also used to calculate the correlations between clinic BP and ABP or daytime and nighttime BP values before and during treatment. A P<0.05 was taken as the level of statistical significance. Data are shown as mean+SD or 95% CIs.
Results

BP Changes With Treatment
ABP monitoring was performed in 422 patients either at baseline or after 6 or 24 months of treatment. Table 1 shows that demographic and clinical characteristics at baseline were comparable in the 3 treated groups. This was also the case for baseline clinic and 24-hour SBP and DBP, which were much lower than clinic SBP and DBP. Additionally, SBP and DBP values were much less during the night when compared with daytime ( Figure 1 ). This was the case also for heart rate whose 24 hour values were similar to clinic values with no betweengroup differences. As shown in Figure 2 , in these 422 patients treatment, significantly reduced 24-hour SBP and DBP from the pretreatment values. The reduction was similar in the telmisartan and ramipril groups but significantly and markedly greater in the group under combination treatment, which also showed SBP and DBP smoothness index values that were almost twice as large as those seen in the monotherapy group ( Figure 3 ). In all 3 groups, BP reduction induced by treatment was greater for clinic BP than for ABP, for the day than for the night (during which the BP reduction was small and often not significant) and for SBP than for DBP.
Absolute On-Treatment SBP and DBP
A total of 830 patients had 1 ABP monitoring between 6 and 24 months after initiation of treatment. As shown in Table 2 , clinic SBP was similar, whereas ambulatory SBP was lower in the telmisartan than in the ramipril group, the mean difference achieving statistical significance for 24 
Correlations and Differences Between Baseline and On-Treatment Clinic and ABP
In the 422 patients in whom baseline and on-treatment values were available, correlations between clinic and 24-hour BP values were significant but not close either for SBP (correlation coefficient 0.39 and 0.58 at baseline and during treatment, respectively; P<0.0001 for both) or for DBP (correlation coefficient 0.51 and 0.49; P<0.0001 for both). Treatment-induced changes of clinic and 24-hour SBP and DBP were even less closely related (0.33 and 0.24, respectively; P<0.0001 for both). Figure 5 shows that in all available patients the marked differences between clinic and 24-hour or daytime SBP and DBP seen at baseline became progressively smaller in patients achieving a progressively lower target clinic SBP with treatment and that the 2 sets of values were substantially similar in the group in which clinic SBP was reduced to <120 mm Hg. 
Discussion
Our study shows that in the ONTARGET patients of the ABP substudy, telmisartan caused a similar or only slightly greater reduction of ABP than ramipril. It also shows that the reduction was much more pronounced in patients under combination with the 2 drugs in whom the BP-lowering effect was at least twice as large as that associated with one or the other monotherapy throughout the day and night. This rules out the possibility that in ONTARGET the ramipril-telmisartan combination did not lead to a greater CV or renal protection 1,26 because of a limited effect on daily life BP, a variable of important prognostic significance. On the contrary, the combination lowered daily life BP even more clearly than could be inferred from clinic BP measurements, with also a greater smoothness index and thus a greater between-hour consistency of the antihypertensive effect and a lower BP variability, a parameter that has been shown to have independent prognostic significance. [27] [28] [29] [30] This implies that other explanations should be sought for the failure of the combination to improve CV or renal outcome compared with the combination components in monotherapy. We can speculate that at the doses used in ONTARGET, double blockade of the renin-angiotensin system had direct harmful effects that neutralized the protection associated with the greater ABP reduction. It is also possible, however, that because initial ABP values were largely within the normal range 24,31 their relationship with events was flatter than at higher values, with thus no substantial effect of greater or smaller treatment-induced changes. We cannot exclude that larger ABP reductions from initially normal values had a detrimental effect, a J curve-like phenomenon 32 that masked a greater benefit of the more complete blockade of the reninangiotensin system provided by the combination. An interesting additional finding of our study is that while in baseline conditions ABP values were markedly lower than the clinic ones, the difference was less during treatment and more so as clinic BP achieved a progressively lower target. Indeed, when the target was set at <130 mm Hg (the value recommended by guidelines for high CV risk individuals such as those from ONTARGET), 24 daytime ABP was <1 mm Hg lower than clinic BP and day and 24-hour BP values were superimposable with clinic BP in patients in whom the clinic BP target was <120 mm Hg, that is, the value aimed at in the more intensively treated high CV risk patients of the action to control cardiovascular risk in diabetes mellitus study. 25 The reasons for this decreasing clinic-ABP difference from baseline to progressively more aggressive treatments are not explained by our study, although we can speculate that several factors (eg, regression dilution, waning of the white coat effect, and resistance to treatment of daily life BP) may be involved. The results, however, are relevant to the debated question of which ABP values should be recommended for treatment, an issue on which there is no direct evidence because no eventbased trial has so far systematically measured ABP before and at various times during treatment. 33 In this context, our study suggests that daytime or 24-hour BP targets for treatment may not be too different from the clinic ones, particularly when, as in patients at high CV risk, a tighter clinic BP control is pursued. Several other results of our study are noteworthy. First, in the ONTARGET patients, the ambulatory SBP reductions induced by telmisartan, ramipril, and the combination of the 2 drugs were all greater than the 24-hour DBP reductions, which means that the BP-lowering effect includes a reduction of pulse pressure. Because in elderly patients like those of ONTARGET pulse pressure has prognostic significance, 34, 35 this can be regarded as a potentially favorable effect common to all treatments used. In line with the results of previous studies, 36 daytime BP was reduced by treatment more than nighttime BP on which the effect was usually so small as to make differences from baseline values not statistically significant. This may have occurred because the drugs were given in the morning, which made their concentration in blood and tissues lower at night. It may also be explained, however, by the law of initial value, that is, irrespective of the treatment used, the magnitude of a BP reduction is directly related to the initial BP value, which is much lower during the night than during the day. Clinic BP and ABP values were significantly related to each other, but the correlation coefficients were low. This was even more the case for their treatment-induced changes, which confirms previous evidence that individual patient measurements made in the clinic environment do not provide an accurate assessment of daily life BP, including its modification by treatment. [7] [8] [9] [10] This represents an additional argument in favor of an extensive use of ABP in future trials of the beneficial effects of antihypertensive drugs.
Our study has strengths and limitations. An important strength is that BP data were carefully checked for quality, which led to the inclusion in the data analysis of only ABP with adequate data. An important limitation, on the other hand, is that, as in all previous ABP data collected in trials, ABP data were collected from nonrandomized patients who were a small fraction of the overall ONTARGET population. This raises the question of whether the present findings are representative of those of the ONTARGET as a whole. Although remaining unproven, we suggest that this may be the case, because most baseline demographic and clinical characteristics of the patients did not differ significantly from those reported in the main study (Table 1 ). Furthermore, in the overall ONTARGET patients, the clinic BP values at runin (141.8/82.1 mm Hg) were not substantially different from those of the ABP monitoring patients. This was the case also for the BP reductions between 6 and 24 months of treatment which in all ONTARGET patients were on average 5.4/4.4, 4.4/3.3, and 7.8/4.9 mm Hg for the telmisartan, ramipril, or their combination groups, respectively. 
Perspectives
The ONTARGET ABP monitoring substudy shows that the telmisartan/ramipril combination induced a substantially greater ABP reduction compared with telmisartan or ramipril alone. This rules out the possibility that the combination did not protect patients more than the monotherapies because it failed to more effectively control a variable of important prognostic significance, such as daily life BP. Furthermore, our data confirm that, in individual patients, significant discrepancies exist between the information offered by clinic BP and ABP monitoring both at baseline and during treatment, which emphasizes the need to obtain systematic information on daily life BP in outcome trials. Finally, our data shed light on the quantitative relationship between clinic BP and ABP before and during treatment. The main finding is that, whereas before treatment ABP is much lower than clinic BP, the 2 sets of values come closer during treatment and are similar in patients under stricter clinic BP control. This is relevant to the debated question of what should be the ABP target.
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